Summary
Beigene, Ltd. reported a significant increase in cash and cash equivalents, reaching $643.5 million as of September 30, 2018, up from $239.6 million at the end of 2017. This liquidity boost was largely driven by successful public offerings, including a dual listing on the Hong Kong Stock Exchange. Despite this strong cash position, the company experienced a substantial net loss of $144.0 million for the third quarter and $405.5 million for the first nine months of 2018, primarily due to continued high research and development expenses. Revenue streams shifted significantly, with collaboration revenue decreasing by 93% in Q3 and 78% year-to-date, while product revenue from the distribution of Celgene's oncology drugs in China saw a significant increase of 336% in Q3 and 956% year-to-date. The company continues to invest heavily in its pipeline, with R&D expenses climbing 68% in Q3 and 137% year-to-date, driven by the advancement of key drug candidates like zanubrutinib and tislelizumab. The company also advanced its commercialization efforts in China for in-licensed Celgene products. While the company has a robust cash balance, the substantial ongoing investment in R&D and increasing SG&A expenses, coupled with the lack of internally developed product revenues to date, indicate a continued need for capital to fund operations and development.
Financial Highlights
55 data points| Revenue | $54.20M |
| Cost of Revenue | $8.71M |
| Gross Profit | $45.50M |
| R&D Expenses | $147.59M |
| SG&A Expenses | $48.82M |
| Operating Expenses | $205.30M |
| Operating Income | -$151.10M |
| Interest Expense | $830K |
| Net Income | -$144.49M |
| EPS (Basic) | $-0.19 |
| EPS (Diluted) | $-0.19 |
| Shares Outstanding (Basic) | 739.79M |
| Shares Outstanding (Diluted) | 739.79M |
Key Highlights
- 1Strong liquidity position with $643.5 million in cash and cash equivalents as of September 30, 2018.
- 2Significant increase in product revenue (336% Q3, 956% YTD) from sales of in-licensed drugs in China.
- 3Collaboration revenue declined significantly (-93% Q3, -78% YTD) due to the upfront payment recognition in the prior year.
- 4Research and development expenses increased substantially (68% Q3, 137% YTD) to support clinical trials of key drug candidates.
- 5Net loss for the nine months ended September 30, 2018, was $405.5 million, compared to a net profit of $6.2 million in the prior year period, largely due to increased R&D spending and the absence of large upfront collaboration payments.
- 6Successful dual listing on the Hong Kong Stock Exchange in August 2018, bolstering the company's cash position.
- 7Continued investment in expanding commercial operations in China and advancing a pipeline of oncology drug candidates.